CCR9 Antagonist Compounds for Treating Inflammation
Summary
The USPTO granted Patent US12611404B2 to ChemoCentrix, Inc. on April 28, 2026, covering aza-aryl 1H-pyrazol-1-yl benzene sulfonamide compounds that function as CCR9 receptor antagonists. The patent lists 10 named inventors including Xi Chen, Junfa Fan, and Pingchen Fan. Animal testing cited in the abstract demonstrates these aryl sulfonamide derivatives are useful for treating inflammation, a CCR9-mediated disease, and may also be used as controls in assays for identifying CCR9 antagonists. The patent application was filed on October 29, 2021.
“The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
The USPTO issued Patent US12611404B2 to ChemoCentrix, Inc. on April 28, 2026, covering specific aza-aryl 1H-pyrazol-1-yl benzene sulfonamide compounds as CCR9 receptor antagonists. The patent grants exclusive rights to these compounds for pharmaceutical applications related to CCR9-mediated diseases and inflammation treatment, as well as their use in assays for identifying CCR9 antagonists. Pharmaceutical companies developing CCR9-targeted therapeutics or inflammatory disease treatments should be aware of this existing patent estate when designing R&D programs or seeking to develop similar compounds, as the 10 claims narrowly define specific aryl sulfonamide derivatives and their pharmaceutical uses.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides
Grant US12611404B2 Kind: B2 Apr 28, 2026
Assignee
CHEMOCENTRYX, INC.
Inventors
Xi Chen, Junfa Fan, Pingchen Fan, Antoni Krasinski, Lianfa Li, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
Abstract
Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.
CPC Classifications
A61K 31/415 A61K 31/4709 A61K 31/4725 A61K 31/502 A61K 31/517 A61K 31/5377 A61K 45/06 A61P 1/00 A61P 1/04 A61P 1/16 A61P 11/00 A61P 11/02 A61P 11/06 A61P 13/12 A61P 15/02 A61P 17/00 A61P 17/04 A61P 17/06 A61P 19/00 A61P 19/02 A61P 25/28 A61P 27/02 A61P 29/00 A61P 3/10 A61P 31/00 A61P 31/18 A61P 35/00 A61P 35/02 A61P 37/00 A61P 37/02 A61P 37/06 A61P 37/08 A61P 39/06 A61P 43/00 A61P 9/10 C07D 231/42 C07D 401/04 C07D 401/06 C07D 401/10 C07D 403/04 C07D 403/10 C07D 405/14
Filing Date
2021-10-29
Application No.
17452946
Claims
10
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.